Abstract:The neurotoxicity associated to the anticancer treatments has received a growing body of interest in the recent years. The development of innovating therapies over the last 20years has led to the emergence of new toxicities. Their diagnosis and management can be challenging in the clinical practice and further research is warranted to improve the understanding of their pathogenic mechanisms. Conventional treatments as radiation therapy and chemotherapy are associated to well-known and under exploration emerging central nervous system (CNS) and peripheral nervous system (PNS) toxicities. The identification of the risk factors and a better understanding of their pathogeny through a "bench to bedside and back again" approach, are the first steps towards the development of toxicity mitigation strategies. New imaging techniques and biological explorations are invaluable for their diagnosis. Immunotherapies have changed the cancer treatment paradigm from tumor cell centered to immune modulation towards an efficient anticancer immune response. The use of the immune checkpoints inhibitors (ICI) and CAR-T cells (chimeric antigen receptor) lead to an increase in the incidence of immune-mediated toxicities and new challenges in the neurological patient's management. The neurological ICI related adverse events (n-irAE) are rare but potentially severe and may present with both CNS and PNS involvement. The most frequent and well characterized, from a clinical and biological standpoint, are the PNS phenotypes: myositis and polyradiculoneuropathy, but the knowledge on CNS phenotypes and their treatments is expanding. The n-irAE management requires a good balance between dampening the autoimmune toxicity without impairing the anticancer immunity. The adoptive cell therapies as CAR-T cells, a promising anticancer strategy, trigger cellular activation and massive production of proinflammatory cytokines inducing frequent and sometime severe toxicity known as cytokine release syndrome and immune effector cell-associated neurologic syndrome. Their management requires a close partnership between oncologist-hematologists, neurologists, and intensivists. The oncological patient's management requires a multidisciplinary clinical team (oncologist, neurologist and paramedical) as well as a research team leading towards a better understanding and a better management of the neurological toxicities.

Neuro-ophthalmic complications of modern anti-cancer drugs

Ocular Surface Side Effects of Novel Anticancer Drugs

Neurologic Complications of Cancer Immunotherapy

Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies

[Ocular surface adverse reactions of antitumor-targeted drugs]

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review

Recent advances in neuro-ophthalmology

Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature

Neurological complications of modern radiotherapy for head and neck cancer

Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy

Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy

Review of recent advances in managing periocular skin malignancies

Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review

Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies

Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy

Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents

Central nervous system injury from novel cancer immunotherapies

Management of Neurologic Complications in Patients with Brain and Spine Tumors

Ocular Immune-Related Adverse Events Associated with PD-1 Inhibitors: From Molecular Mechanisms to Clinical Management

Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies